Formula I Compounds Inducing Apoptosis in Cancer Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments often lack effective molecules that can induce apoptosis or arrest the cell cycle, particularly in cancer cells, leading to inadequate therapeutic outcomes for various types of cancer.
Innovation Solution
Compounds of Formula (I), their salts, isomers, and derivatives, such as esters, ethers, or amides, are used in compositions that induce apoptosis or cause arrest in the G2/M phase of the cell cycle, with concentrations ranging from 0.20% to 90% by weight, specifically targeting cancer cells like DU145 and PC-3 cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then treatment is provided, but they lack effective molecules that can induce apoptosis or arrest the cell cycle
Solution Approach 1:
The patent modifies the chemical structure of withanolide compounds by varying substituents at positions R1, R2, and R3 (H, hydroxyl, halogen, methyl, ethyl, methoxy, or ethoxy) to optimize biological activity. This structural parameter optimization enables the compounds to effectively induce apoptosis and arrest cell cycle at G2/M phase, directly resolving the deficiency of current cancer treatments lacking effective apoptotic-inducing molecules
2Object-affected harmful factors
If compounds of Formula (I) are used at high concentrations, then cytotoxic activity against cancer cells is enhanced, but the complexity of formulation and delivery increases
Solution Approach 1:
The patent specifies optimal concentration ranges (0.20% to 90% by weight, with preferred ranges of at least 10.0%, 50.0%, or 90.0% by weight) to maximize cytotoxic activity while maintaining manageable formulation complexity. This parameter optimization allows high therapeutic efficacy without excessive formulation complexity
Solution Approach 2:
The patent creates pharmaceutical compositions that combine compounds of Formula (I) with formulary ingredients and pyrogen-free water, forming composite materials that facilitate delivery while maintaining high cytotoxic activity. This composite approach enables effective cancer cell targeting without overwhelming formulation complexity
Data Source
AI summary
Certain embodiments of the invention include compositions comprising a compound of Formula (I), and salts, isomers, and derivatives thereof. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I), and salts, isomers, and derivatives thereof. Other embodiments of this invention include methods for treating disease (e.g., cancer) and methods for administering a compound of Formula (I), and salts, isomers, and derivatives thereof.